1,139 results on '"Mufti, G."'
Search Results
2. MASS CYTOMETRY REVEALS A DISTINCT IMMUNOPHENOTYPE IN TELOMEROPATHIES
3. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
4. Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia
5. Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes
6. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT
7. MDS as an Autoimmune Process
8. The Myelodysplastic Overlap Syndromes
9. Preclinical modeling of myelodysplastic syndromes
10. Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party
11. Clinical significance of acquired somatic mutations in aplastic anaemia
12. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes
13. Therapeutic Implications of Understanding Pathogenesis: Clinical Relevance of Prognostic Factors
14. Discussion
15. Non-Myeloablative Stem Cell Transplantation for Congenital Immunodeficiencies
16. High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS)
17. A multicentre UK study of GVHD following DLI: Rates of GVHD are high but mortality from GVHD is infrequent
18. Retrospective study of alemtuzumab vs ATG-based conditioning without irradiation for unrelated and matched sibling donor transplants in acquired severe aplastic anemia: a study from the British Society for Blood and Marrow Transplantation
19. Anti-phospholipase A2 receptor (Anti-PLA2R) antibody positive-nephrotic syndrome as a manifestation of multi-system, immunemediated complications post allogeneic stem cell transplant: A case report: 410
20. FLAG-lite regimen is effective bridging salvage chemotherapy for relapsed/refractory acute myeloid Leukaemia - a single centre experience: 336
21. Germline mutations of hTERT in myelodysplastic syndromes are associated with shortened telomeres but are not associated with increased cytogenetic abnormalities: 298
22. A comparison of PCR methods for the detection of MYD88 L265P mutations in a diagnostic setting: 193
23. T-cell depletion with anti-thymocyte globulin (ATG) favours superior overall survival and lowers rates of relapse and GVHD when compared to alemtuzumab in patients undergoing allogeneic haematopoietic stem cell transplantation for myelofibrosis: A retrospective single centre analysis: 21
24. Single UK centre outcomes of peripheral blood stem cell (PBSC) haploidentical transplantation: 20
25. Feasibility and optimal schedule of eculizumab in patients with haemolytic paroxysmal nocturnal hemoglobinuria (hPNH) with severe aplastic anaemia (SAA) prior to haemopoietic stem cell transplant (HSCT): 22
26. Targeted sequencing of 647 patients with myeloid malignancies, marrow failures and cytopenia: A prospective ‘real life’ analysis: 17
27. Life coaching following haematopoietic stem cell transplantation: a mixed-method investigation of feasibility and acceptability
28. PTU-079 Non-invasive testing is diagnostic and prognostic in intestinal graft versus host disease
29. OC-031 Rectogismoid biopsies are sufficient to confirm intestinal involvement in symptomatic patients with acute or chronic graft versus host disease: a retrospective observational study
30. Donor lymphocyte infusion - a retrospective single centre audit: 13
31. Immunological profile of patients after HSCT using the FCC conditioning regimen for treatment of severe aplastic anemia indicates potential basis for tolerance with mixed T-cell chimerism and extremely low incidence of GvHD: 12
32. Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial
33. Allogeneic stem cell transplantation using alemtuzumab-containing regimens in severe aplastic anemia
34. The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT
35. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group
36. Efficacy of bimonthly extracorporeal photopheresis in refractory chronic mucocutaneous GVHD
37. Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide
38. Allogeneic haematopoietic SCT for chronic myelomonocytic leukaemia: a single-centre experience
39. Reducing MCM levels in human primary T cells during the G0→G1 transition causes genomic instability during the first cell cycle
40. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML
41. RETROSPECTIVE COMPARISON OF HPC-A COLLECTION EFFICIENCY BETWEEN SPECTRA OPTIA® AND COBE SPECTRA® CELL SEPARATORS IN A LARGE TERTIARY COLLECTION FACILITY.: PH-AB200
42. EBV REACTIVATION AND PTLD IN PATIENTS RECEIVING HSCT FOR APLASTIC ANAEMIA: PH-AB075
43. PREDICTING FACTORS FOR INPATIENT MORTALITY AND LONG TERM SURVIVAL IN ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS ADMITTED TO INTENSIVE CARE UNIT: PH-P317
44. Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant
45. Tumor-derived IL-6 may contribute to the immunological defect in CLL
46. The clinical and histopathological spectrum of neutrophilic inflammatory disease encountered in the setting of myelodysplastic syndrome
47. Clonal gammopathies following alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation: association with chronic graft-versus-host disease and improved overall survival
48. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine
49. Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin
50. Ten years outcome analysis of corporeal plication for Peyronie’s Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.